Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

mpany announced that the first study (Study 102) met its primary 48-week efficacy endpoint showing that Viread is non-inferior to Hepsera among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic hepatitis B.

"The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, Clinical Research, Gilead Sciences. "We look forward to reviewing these data with regulatory authorities and are working quickly to file a New Drug Application in the United States and Marketing Authorisation Application in Europe in the fourth quarter of this year."

The active ingredient in Viread, tenofovir DF, is currently the most prescribed molecule in the United States for combination HIV therapy. Viread received approval as an anti-HIV medication from the U.S. Food and Drug Administration (FDA) in October 2001 and from the European Commission in February 2002. Viread is not approved as a treatment for chronic hepatitis B, and data from this analysis have not been reviewed by the FDA.

Study Design

Study 103 is a multi-center, randomized, double-blind Phase III clinical trial that compares the efficacy, safety and tolerability of Viread and Hepsera over 48 weeks among patients with HBeAg-positive chronic hepatitis B. Two hundred and sixty-six patients were randomized in a 2:1 ratio to receive either Viread (300 mg once daily; n=176) or Hepsera (10 mg once daily; n=90).

About Viread (tenofovir disoproxil fumarate)

In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread should not be used in combination with the fixed-dose combination products Truvada(R) or Atripla(TM) because they already contain Viread.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the u
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 2007 /PRNewswire/ -- DNA Therapeutics,S.A. an emerging pharmaceutical ... elucidation of a new mechanism,of action and the ... molecule Dbait. It will be,presented at the forecoming ... abstract is now available online.,The presentation itself will ...
... Potent Synergy, Activity and Patient Tolerance Support ... Spain, April 12, 2007 /PRNewswire/ -- Intarcia,Therapeutics, ... final results from a Phase 2 study ... treatment-naive patients,with genotype 1 chronic hepatitis C. ...
Cached Medicine Technology:DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 2DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4
(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) -- ... But it was a physical challenge in her childhood ... sport. "I was an 11-year-old girl with my ... diagnosed by my orthopedic surgeon," said Lewis, who has ... and the American Academy of Orthopaedic Surgeons so she ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... found that the United States, which has the most expensive ... rich countries for quality, access and efficiency of healthcare. ... performance, to other countries and differs most notably in the ... to the studies. ,Says Commonwealth Fund president ...
... experts in India are questioning the efficacy of the ... the country. The increasing number of TB cases ... with how the DOTS strategy has been implemented, according ... has implemented various TB control programs that are used ...
... on Tuesday said that Thailand will not issue compulsory ... if pharmaceutical companies offer prices lower than those charged ... came one day after Abbott Laboratories and Thailand failed ... antiretroviral drugs Aluvia and Kaletra. ,The Thai ...
... in doctors reflects the reality in the NHS. It is ... doctors to improve the quality and experience of care for ... service. ,In virtually all of the questions patients ... answered that doctors are providing high standards of care. ...
... most common but contentious accommodation requests made by students ... entrance and licensing exams. According to a new study ... time respond to exams similarly to average students under ... there is no real evidence to suggest that the ...
... East Anglia in Norwich and Kings College in London, has ... used to find out not only the kind of drugs ... diseases. ,Lead researcher, David A. Russell, and his ... about the lifestyle of the person whose fingerprints have been ...
Cached Medicine News:Health News:Americans Get Least Value For Money In Healthcare 2Health News:Thailand Will Not Issue Compulsory Licenses for Patented Drugs 2Health News:Now Fingerprints can Be Used to Detect Drugs and Diseases Instead of Blood Samples 2
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Marco Radiusgauges are available with either a ... in either monocular or binocular form. All ... one, measuring both the curvature and thickness ... The accuracy of both measurements is increased ...
... or for those seeking high quality ... is an economical, full-function instrument-delivery system. ... body offer rugged, maintenance-free service. And ... two arms provided as standard equipment--adjusts ...
... Marco could offer you a choice of two ... Chart Projector uses a halogen bulb for longer ... use. The Marco Chart Projector offers a lower ... includes a thermistor for extended bulb life. And ...
Medicine Products: